cepia

Clinical Epidemiology and Ageing

Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.

Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, Pouget F, Viallette C, Wolkenstein P, Bastuji-Garin S Dermatology. 2009;219(2):148-54.

BACKGROUND: Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available.

OBJECTIVE: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS.

METHODS: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment.

RESULTS: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects.

CONCLUSION: The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

MeSH terms: Administration, Oral; Clindamycin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hidradenitis Suppurativa; Humans; Male; Patient Satisfaction; Quality of Life; Retrospective Studies; Rifampin; Severity of Illness Index; Treatment Outcome
DOI: 10.1159/000228334